Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fufang Xueshuantong
- Development stage
- Unknown
- Lead developer
- Zhongsheng Pharma
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Fufang Xueshuantong is a standardized Traditional Chinese Medicine (TCM) compound formulation widely utilized in China for the treatment of vascular retinal diseases and cardiovascular conditions. It is composed of four primary herbal ingredients: *Panax notoginseng* (Sanqi), *Astragalus membranaceus* (Huangqi), *Salvia miltiorrhiza* (Danshen), and *Scrophularia ningpoensis* (Xuanshen). The formulation is designed to promote blood circulation, resolve blood stasis, and nourish "Qi" and "Yin". In clinical practice, it is primarily indicated for stable exertional angina pectoris and retinal vascular disorders, including diabetic retinopathy and retinal vein occlusion. Its therapeutic effects include improving microvascular perfusion, reducing blood viscosity, and exerting anti-inflammatory and anti-oxidative properties. In ophthalmology, it is frequently investigated as an adjunctive therapy to anti-VEGF agents for conditions such as choroidal neovascularization (CNV) to enhance visual outcomes and reduce retinal edema.
- Brand names
- Fufang Xueshuantong
- Other names
- Compound XueshuantongFufang Xueshuantong Capsules
02
Targets
ACE (Angiotensin Converting Enzyme)STAT3 (Signal Transducer and Activator of Transcription 3)HIF1A (Hypoxia-inducible factor 1-alpha)STAT1 (Signal transducer and activator of transcription protein 1)
Beyond the preview
Go deeper on Fufang Xueshuantong.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fufang Xueshuantong.